文献速递消化道肿瘤与早癌

二甲双胍使用与食管鳞状细胞癌风险的相关性:一项基于人群的队列研究

Association Between Metformin Use and Risk of Esophageal Squamous Cell Carcinoma in a Population-Based Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该研究基于瑞典2005-2015年全国性前瞻性队列,比较411603名二甲双胍使用者与频率匹配的非使用者,发现二甲双胍使用与食管鳞状细胞癌(ESCC)风险降低相关(HR 0.68,95%CI 0.54-0.85),新使用者及60-69岁人群风险降低更明显。

要点

  • 二甲双胍使用与ESCC风险降低独立相关(HR 0.68)。
  • 新使用二甲双胍者ESCC风险降低更显著(HR 0.44)。
  • 60-69岁年龄组使用二甲双胍者风险降低更明显(HR 0.45)。

核心结论

  • 二甲双胍使用与食管鳞状细胞癌(ESCC)发病风险降低相关。

主要发现

  • 二甲双胍使用者ESCC发病率为3.5/10万人年,非使用者为5.3/10万人年。
  • 总体二甲双胍使用者ESCC风险低于非使用者(HR 0.68,95%CI 0.54-0.85)。
  • 新使用二甲双胍者风险降低更明显(HR 0.44,95%CI 0.28-0.64)。
  • 60-69岁参与者风险降低更明显(HR 0.45,95%CI 0.31-0.66)。

临床怎么用

  • 对于需使用二甲双胍的糖尿病患者,尤其60-69岁或新用药者,可关注其ESCC风险降低的潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Esophageal cancer is a highly fatal malignant neoplasm, with 2 etiologically different histological types. A large prospective study is expected to elucidate the specific risk of the 90% subtype of esophageal cancer, esophageal squamous cell carcinoma (ESCC), with metformin therapy. This study aims to determine the association between metformin use and incident ESCC risk. METHODS: This was a nationwide population-based prospective cohort study conducted in Sweden in 2005-2015. Among 8.4 million participants identified in the cohort, 411,603 (5%) were metformin users. The users were compared with 10 times as many frequency-matched nonusers of metformin (n = 4,116,030) by age and sex. Metformin use was treated as a time-varying variate, and multivariable cause-specific proportional hazards model was used to calculate hazard ratios (HR) with 95% confidence intervals (CI) for ESCC, adjusted for age, sex, calendar year, residence area, tobacco smoking, alcohol overconsumption, and use of nonsteroidal anti-inflammatory drugs or statins. RESULTS: The incidence rates of ESCC were 3.5 per 100,000 person-years among the metformin users and 5.3 per 100,000 person-years in the nonusers. Metformin users overall were at a decreased risk of ESCC compared with nonusers (HR 0.68, 95% CI 0.54-0.85). The decrease in risk was more pronounced in new metformin users (HR 0.44, 95% CI 0.28-0.64) and participants aged 60-69 years (HR 0.45, 95% CI 0.31-0.66). DISCUSSION: Metformin use decreases the risk of developing ESCC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Wang QL, Santoni G, Ness-Jensen E, et al. Association Between Metformin Use and Risk of Esophageal Squamous Cell Carcinoma in a Population-Based Cohort Study. Am J Gastroenterol. 2020. PMID: 31821177. doi:10.14309/ajg.0000000000000478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。